vs
Ategrity Specialty Insurance Co Holdings（ASIC）与IDEAYA Biosciences, Inc.（IDYA）财务数据对比。点击上方公司名可切换其他公司
IDEAYA Biosciences, Inc.的季度营收约是Ategrity Specialty Insurance Co Holdings的1.8倍（$207.8M vs $116.1M），IDEAYA Biosciences, Inc.净利率更高（57.4% vs 19.5%，领先37.9%）
Ategrity Specialty Insurance Co Holdings是一家特种保险控股企业，提供商业财产及意外伤害保险解决方案，主营超额与盈余线保险业务，服务美国本土建筑、医疗、小型企业等细分领域，为标准保险公司通常不承接的特殊风险提供定制化保单。
IDEAYA Biosciences是一家临床阶段生物技术企业，专注于肿瘤学领域，研发针对基因定义癌症的靶向疗法及合成致死治疗方案，推进多肿瘤类型的候选药物管线开发，与行业伙伴合作提升全球创新癌症治疗方案的可及性。
ASIC vs IDYA — 直观对比
营收规模更大
IDYA
是对方的1.8倍
$116.1M
净利率更高
IDYA
高出37.9%
19.5%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.1M | $207.8M |
| 净利润 | $22.7M | $119.2M |
| 毛利率 | — | — |
| 营业利润率 | 25.6% | 52.2% |
| 净利率 | 19.5% | 57.4% |
| 营收同比 | — | — |
| 净利润同比 | — | 330.1% |
| 每股收益（稀释后） | $0.45 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASICIDYA
| Q3 25 | $116.1M | $207.8M | ||
| Q2 25 | $101.8M | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 | ||
| Q3 22 | — | $29.7M |
净利润ASICIDYA
| Q3 25 | $22.7M | $119.2M | ||
| Q2 25 | $17.6M | — | ||
| Q3 24 | — | $-51.8M | ||
| Q2 24 | — | $-52.8M | ||
| Q1 24 | — | $-39.6M | ||
| Q3 22 | — | $1.6M |
营业利润率ASICIDYA
| Q3 25 | 25.6% | 52.2% | ||
| Q2 25 | 21.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 2.2% |
净利率ASICIDYA
| Q3 25 | 19.5% | 57.4% | ||
| Q2 25 | 17.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 5.4% |
每股收益（稀释后）ASICIDYA
| Q3 25 | $0.45 | $1.33 | ||
| Q2 25 | $0.39 | — | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.68 | ||
| Q1 24 | — | $-0.53 | ||
| Q3 22 | — | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.3M | $786.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $588.6M | $1.1B |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASICIDYA
| Q3 25 | $34.3M | $786.9M | ||
| Q2 25 | $23.5M | — | ||
| Q3 24 | — | $920.0M | ||
| Q2 24 | — | $701.7M | ||
| Q1 24 | — | $698.8M | ||
| Q3 22 | — | $386.2M |
股东权益ASICIDYA
| Q3 25 | $588.6M | $1.1B | ||
| Q2 25 | $559.7M | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $931.7M | ||
| Q1 24 | — | $935.3M | ||
| Q3 22 | — | $368.8M |
总资产ASICIDYA
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $973.7M | ||
| Q1 24 | — | $961.5M | ||
| Q3 22 | — | $410.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $41.1M | $142.2M |
| 自由现金流经营现金流 - 资本支出 | — | $142.2M |
| 自由现金流率自由现金流/营收 | — | 68.4% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 1.81× | 1.19× |
| 过去12个月自由现金流最近4个季度 | — | $13.5M |
8季度趋势，按日历期对齐
经营现金流ASICIDYA
| Q3 25 | $41.1M | $142.2M | ||
| Q2 25 | $50.8M | — | ||
| Q3 24 | — | $-49.2M | ||
| Q2 24 | — | $-32.9M | ||
| Q1 24 | — | $-43.8M | ||
| Q3 22 | — | $-24.2M |
自由现金流ASICIDYA
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M | ||
| Q3 22 | — | $-25.3M |
自由现金流率ASICIDYA
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | -85.1% |
资本支出强度ASICIDYA
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 3.7% |
现金转化率ASICIDYA
| Q3 25 | 1.81× | 1.19× | ||
| Q2 25 | 2.88× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | -14.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
